Phase 3Not yet recruiting
Dapagliflozin for Long COVID Syndrome (DALCO)
- Sponsor
- Ottawa Heart Institute Research Corporation (Academic or other)
- Enrollment
- 192 planned
- Conditions
- COVID - 19; Long COVID Syndrome; SARS CoV-2
- Interventions
- Dapagliflozin (DAPA); Placebo
- Ages
- adults, older adults
- Registry
- NCT06907251
Full record on ClinicalTrials.gov
From the registry
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Primary outcomes
- 6 month change in EQ-5D derived utility score.
History
Study completion expected
Primary completion expected
Expected to start
Last registry update
Registered